ABO血液型不適合移植の新戦略―2011―

出版社： 日本医学館
著者：
発行日： 2011-07-15
分野： 臨床医学：外科  >  移植/人工臓器
ISBN： 9784890447282
電子書籍版： 2011-07-15 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

商品紹介

第17回日本ABO血液型不適合移植研究会の成果をまとめたもの。「ABO血液型不適合臓器移植における免疫抑制療法」を主題に、腎移植、肝移植それぞれの現況や症例などを報告する。

目次

  • ABO血液型不適合移植の新戦略―2011―

    ―目次―

    第17回日本ABO血液型不適合移植研究会
    主題：ABO血液型不適合臓器移植における免疫抑制療法

    統計
    　日本におけるABO血液型不適合腎移植の統計2010

    腎移植
    　1．リツキシマブ、バシリキシマブを用い脾臓摘出を回避した
    　　　ABO血液型不適合腎移植症例
    　2．脾臓摘出を行わないABO血液型不適合腎移植の成績
    　3．新潟大学におけるABO血液型不適合腎移植

    肝移植
    　肝類洞内皮細胞による血液型糖鎖抗原認識B細胞の寛容化において
    　　Fas/Fas-ligand pathwayは主要な役割を果たさない

    コンセンサスシンポジウム
    　“当科におけるABO血液型不適合肝移植の現況とあらたな工夫”
    　1．九州大学における門脈・動脈注入療法を用いない
    　　　ABO血液型不適合肝移植
    　2．広島大学におけるABO血液型不適合肝移植の現況と
    　　　iNKT細胞制御による特異的減感作療法の可能性
    　3．京都大学におけるABO血液型不適合成人生体肝移植の
    　　　現況とあらたな工夫
    　4．慶應義塾大学におけるABO血液型不適合生体肝移植の
    　　　現況とあらたな工夫
    　総合討論

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第17回日本ABO血液型不適合移植研究会 主題 : ABO血液型不適合臓器移植における免疫抑制療法

P.13 掲載の参考文献
1) Takahashi K, Saito K, Tanabe K et al.:Multicenter cooperative study group. First report of a seven-year survey on ABO-incompatible kidney transplantation in Japan. Clin Exp Nephrol 5:119-125, 2001.
 
2) Takahashi K, Saito K, Takahara S et al.:Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4:1089-1096, 2004.
PubMed
3) Takahashi K, Saito K:The Japanese ABO-incompatible Kidney Transplantation Committee:Present status of ABO-incompatible kidney transplantation in Japan. Xeno-transplant 13:118-122, 2006.
 
4) Takahashi K:ABO-incompatible organ transplantation. Curr Opin Organ Transplant 12:409-414, 2007.
 
5) Takahashi K:Chapter 6. Accommodation in ABO-incompatible kidney transplantation-Why do kidney grafts survive? Accommodation in ABO-incompatible Kidney Transplantation. Elsevier, Amsterdam, 2004, p37-52.
 
6) Takahashi K:A new concept of accommodation in ABO-incompatible kidney transplantation. Clin. Transplant 19 (suppl 14) :76-85, 2005.
 
7) Takahashi K:Anew immunosuppressive therapy in ABO-incompatible kidney transplantation besed on a new concept of accommodation. ABO-incompatible Organ Transplantation from Japan. (ed. Takahashi K) , Elsevier, Amsterdam, 2006, p73-87.
 
8) Ogawa H, Mohiuddin MM, Galili U et al.:Mouse-heart grafts expressing an incompatible carbohydrate antigen. II Transition from accommodation to tolerance. Transplantation 77:366-373, 2004.
PubMed
9) Galili U:Xenotransplantation and ABO-incompatible transplantation; the similarities they share. Transfus Apher 35:45-58, 2006.
PubMed
10) West LJ:B-cell tolerance following ABO-incompatible heart transplantation. Transplantation 81:301-307,
PubMed
11) Takahashi K:Chapter 8. Timing of the start of immuno-suppressive therapy (duration of desensitization therapy) . Accommodation in ABO-incompatible Kidney Transplantation. Elsevier, Amsterdam, 2004, p94-95
 
12) Takahashi K:ABO-incompatible kidney transplantation-Establishing a scientific framework. Elsevier, Amsterdam, 2007, p38-52.
 
13) Saito K, Nakagawa Y, Takahashi K et al.:Pinpoint targeted immunosuppression; Anti-CD20/MMF desensitization with anti-CD25 in successfUI ABO-incompatible kidney transplantation without splenectomy. Xenotransplant 13:111-117, 2006.
 
14) Takahashi K:Recent findings of ABO-incompatible kidney transplantation-Classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-bloog group-related antigens during critical period preceding establishment of accommodation. Clin Exp Nephrol 11:128-141, 2007.
 
15) Tyden G, Kumlien G, Genberg H et al.:ABO-incompatible kidney transplantation without splenectomy using antigen-specific immunoadsorption and rituximab. Am J Transplant 5:145-148, 2005.
PubMed
16) Kobayashi T, Saito K:Aseries of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. Xenotransplantation 13:136-140, 2006.
 
17) Alexandre GPJ, Squifflet JP, Bruyere MDE et al.:Splenectomy as a prerequisite for human ABO-incompatible renal transplantation. Transplant Proc 17:138-143, 1985.
 
18) Irei T, Ohdan H, Zhou W et al:The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade:novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110:4567-4575, 2007.
 
19) Tasaki M, Yoshida Y, Miyamoto M et al.:Identification and characterization of major proteins carrying ABO blood group antigens in the human kidney. Transplantation 87:1125-1133, 2009
PubMed
20) Takahashi K, Saito K, Nakagawa Y et al:Mechanism of acute antibody-mediated rejection in ABO-incompatible kidney transplantation:which anti-A/anti-B antibodies areresponsible, natural or de novo? Transplantation 89:635-637, 2010.
PubMed
P.21 掲載の参考文献
1) Okamoto M, Omori Y, Ichida M, Nobori S, Yoshimura N et al.:An autopsy case of bacterial septic shock 12 years following ABO-incompatible renal transplantation. Clin Transplant 18(Suppl 11) :44-49, 2004.
 
2) Kaihara S, Okamoto M, Akioka K, Ogino S, Yoshimura N et al.:Improved graft survival in ABO-incompatible living donor kidney transplantation. Transplant Proc 37(4) :1804-1805, 2005.
PubMed
3) Okamoto M, Omori Y, Kadotani Y, Ushigome H, Yoshimura N et al.:Tacrolimus-based immunosuppression in renal transplantation:78 experiences in a single Japanese center. Transplant Proc 34(5) :1666, 2002.
 
4) Okamoto M, Wakabayashi Y, Higuchi A, Kadotani Y, Yoshimura N et al.:Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. Transplant Proc 35:859-860, 2005.
 
5) Okamoto M, Akioka K, Higuchi A, Kadotani Y, Yoshimura N et al.:Clinicopathological evaluation of renal allograft treated with anti-CD25 monoclonal antibody. Clin Transplant 19(Suppl 14) :49-53, 2005.
 
6) 岡本雅彦, 若林良浩, 昇修治, 樋口濃史, 吉村了勇・他:腎移植におけるシムレクト使用症例20例の臨床的検討. 今日の移植 16:585-586, 2003.
 
7) 岡本雅彦, 牛込秀隆, 昇修治, 吉村了勇:今月の主題「腎移植」腎移植における免疫抑制療法の実際. 臨床検査 52(7) :773-777, 2008.
 
8) 岡本雅彦, 秋岡清一, 牛込秀隆, 荻野史朗, 吉村了勇・他:ABO血液型不適合腎移植における代謝拮抗剤のコンバージョンについて. THERAPEUTIC RESEARCH 26(4) :617-622, 2005.
 
9) 岡本雅彦, 鈴木智之, 藤木真人, 昇修治, 吉村了勇・他:リツキシマブを用いたABO血液型不適合腎移植症例の検討. ABO血液型不適合移植の新戦略-2009. (高橋公太, 田中紘一・編) , 日本医学館, 2009, p43-49.
 
10) 岡本雅彦, 秋岡清一, 昇修治, 牛込秀隆, 吉村了勇・他:当施設における高用量ミゾリビン併用免疫抑制療法の経験. THERAPEUTIC RESEARCH 27(4) :649-653, 2006.
Medical*Online
11) 岡本雅彦:免疫抑制法と感染症:その対策-ミゾリビン. 今日の移植 20(3) :280-283, 2007.
Medical*Online
P.28 掲載の参考文献
1) Shimmura H, Tanabe K, Ishikawa N et al.:Role of anti-A/Bantibody titers in results of ABO-incompatible kidney transplantation. Transplantation 70:1331-1339, 2000.
 
2) Shimmura H, Tanabe K, Ishida H et al.:Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation 80:985-988, 2005.
PubMed
3) Toki D, Ishida H, Setoguchi K et al:Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation:long-term impact and risk factors. Am J Transplant 9:567-577, 2009.
PubMed
4) Tobian A, Shirey R, Montgomery R et al.:ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 10:1247-1253, 2010.
PubMed
P.36 掲載の参考文献
1) Alexandre GPJ, Squifflet JP, Bruyere MDE et al.:ABO incompatible related and unrelated living donor renal allografts. Transplant Proc 18:452-459, 1986.
 
2) Ota K, Takahashi K, Agishi T et al.:Japanese Biosynsorb ABO blood type incompatible kidney transplantation group:Multicenter traial of ABO-incompatible kidney transplantation. Transplant Int 5(suppl) :40-45, 1992.
 
3) Takahashi K:A review of humoral rejection in ABO incompatible kidney transplantation, with local (intrarenal) DIC as the underlying condition. Acta Med Biol 45(3) :95-102, 1997.
 
4) 高橋公太:ABO血液型不適合腎移植における液性拒絶反応の考察. 今日の移植 10:675-681, 1997.
 
5) Onitsuka S, Yamaguchi Y, Takahashi K et al.:Peritubular capillary deposition of C4d complement fragment in ABO-incompatible renal transpiantation with humoral rejection. Clin Transplant 13(suppl 1) :33-36, 1999.
 
6) Saito K, Nakagawa Y, Takahashi K et al.:Efficacy of tacrolimus in ABO incompatible kidney transplantation:clinicopathological aspect of humoral rejection. Transplant Proc 31:2851-2852, 1999.
PubMed
7) Takahashi K:Accommodation in ABO-incompatible kidney transplantation:Why do kidney grafts survive? Transplant Proc 36(suppl 2S) :193S-196S, 2004.
 
8) Takahashi K, Saito K, Tanabe K et al:First report of a seven-year survey on ABO-incompatible kidney transplantation in Japan. Clin Exp Nephrol 5:119-125, 2001.
 
9) Takahashi K, Saito K, Takahara S et al.:Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4:1089-1096, 2004.
PubMed
10) 齋藤和英, 高橋公太:Basiliximab(新しい免疫抑制薬) . 腎と透析 55:581-586, 2003.
 
11) Takahashi K:Accommodation in ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2004.
 
12) Sawada T, Fuchinoue S, Kawasa K et al.:Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 18:254-260, 2004.
 
13) Christopher J, Sonnenday DS, Warrnen MH et al.:Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 4:1315-1322, 2004.
 
14) Takahashi K:Blood group antigens and their antibodies. ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2001, p13-19.
 
15) 高橋公太:ABO血液型不適合腎移植における新しい知見-ABO血液型関連抗原による急性抗体関連型拒絶反応の分類. 移植 24:243-254, 2004.
 
16) 高橋公太:ABO血液型不適合腎移植における最近の知見-ABO血液型不適合移植の新戦略-2007, 日本医学館, 2005, p3-23.
 
17) 田崎正行, 吉田豊, 田口いづみ・他:ヒト腎臓におけるABO血液型抗原を持つ蛋白質のプロテオーム解析. ABO血液型不適合移植の新戦略-2009. 日本医学館, 2008, p30-36.
 
P.42 掲載の参考文献
1) Zhou W, Ohdan H, Tanaka Y, Hara H, Tokita D et al.:NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate deterrninant. Transpl Immunol 12(1) :9-18, 2003.
 
2) Ohdan H, Zhou W, Tanaka Y, Irei T, Fuchimoto Y et al.:Evidence of immune tolerance to blood group antigens in a case of ABO-incompatible pediatric liver transplantation. Am J Transplant 7(9) :2190-2194, 2007.
 
3) 五十嵐友香, 大段秀樹:当科におけるABO血液型不適合肝移植8例の報告. ABO血液型不適合移植の新戦略-2009. 日本医学館, 2009, p78-83.
 
4) Tokita D, Shishida M, Ohdan H et al.:Liver sinusoidal endothelial cells contribute to alloreactive T-cell tolerance induced by portal venous injection of donor splenocytes. Transpl Int 18(2) :237-245, 2005.
 
5) Morita M, Fujino M et al.:PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft. Am J Transplant 10(1) :40-46, 2010.
 
6) 五十嵐友香, 大段秀樹, 伊禮俊充, 志々田将幸, 田中友加, 浅原利正:肝類洞内皮細胞によるB細胞免疫寛容誘導の可能性. ABO血液型不適合移植の新戦略-2008. 日本医学館, 2008, p30-34.
 
P.47 掲載の参考文献
1) Egawa H, Teramukai S, Haga H et al.:Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 47:143-152, 2008.
PubMed
2) Tanabe M, Shimazu M, Wakabayashi G et al.:Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73:1959-1961, 2002.
PubMed
3) Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Maehara Yet al.:Rituximab, IVIG and plasma exchange without graft local infusion treatment; Anew protocol in ABO incompatible living donor liver transplantation. Transplantation 88:303-307, 2009.
 
4) Pescovitz MD:Rituximab, an anti-CD20 monoclonal antibody:history and mechanism of action. Am J Transplant 6:859-866, 2006.
PubMed
5) Usui M, Isaji S, Mizuno S et al.:Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation. Clin Transplant 21:24-31, 2007.
PubMed
6) Egawa H, Ohmori K, Haga H et al:B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl 13:579-588, 2007.
PubMed
7) Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D:Intravenous gammaglobulin(IVIG) :a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 6:459-466, 2006.
PubMed
8) Morioka D, Sekido H, Kubota K et al.:Antibody-mediated rejection after adult ABO-incompatible liver transplantation remedied by gamma-globulin bolus infusion combined with plasmapheresis. Transplantation 78:1225-1228, 2004.
PubMed
9) Ikegami T, Taketomi A, Soejima Y et al.:Successful ABO incompatible living donor liver transplantation in a patient with high isoagglutinin titer using high-dose intravenous immunoglobulin. Transplant Proc 39(10) :3491-3494, 2007.
 
10) Urbani L, Mazzoni A, Bianco I et al.:The role of immunomodulation in ABO-incompatible adult liver transplant recipients. J Clin Apher 23:55-62, 2008.
PubMed
P.55 掲載の参考文献
1) Zhou W, Ohdan H, Tanaka Y, Hara H, Tokita D, Onoe T et al.:NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant. Transpl Immunol 12(1) :9-18, 2003.
 
2) Galli G, Nuti S, Tavarini S, Galli-Stampino L, De Lalla C, Casorati G et al.:CD ld-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med 197 (8) :1051-1057, 2003.
 
3) Tahara H, Ide K, Basnet NB, Tanaka Y, Matsuda H, Takematsu H et al.:Immunological property of antibodies against N-glycolylneuraminic acid epitopes in cytidine monophospho-N-acetylneuraminic acid hydroxylase-deficient mice. J Immunol 184(6) :3269-3275, 2010.
PubMed
4) Irei T, Ohdan H, Zhou W, Ishiyama K, Tanaka Y, Ide K et al.:The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade:novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110(13) :4567-4575, 2007.
 
5) Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E et al.:Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171(3) :1581-1587, 2003.
PubMed
6) Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli Met al.:Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 104(10) :3984-3989, 2007.
 
7) Campos RA, Szczepanik M, Itakura A, Akahira-Azuma M, Sidobre S, Kronenberg M et al.:Cutaneous immunization rapidly activates liver invariant Valpha14 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact sensitivity. J Exp Med 198(12) :1785-1796, 2003.
PubMed
8) Barral P, Eckl-Doma J, Harwood NE, De Santo C, Salio M, Illarionov P et al.:B-cell receptor-mediated uptake of CDld-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc Natl Acad Sci USA 105(24) :8345-8350, 2008.
 
9) Ohdan H, Swenson KG, Kruger Gray HS, Yang YG, Xu Y, Thall AD et al:Mac-1-negative B-1b phenotype of natural antibody-producing cells, including those responding to Gal alpha 1, 3Gal epitopes in alpha 1, 3-galactosyl-transferase-deficient mice. J Immunol 165(10) :5518-5529, 2000.
PubMed
10) Hernandez AM, Toledo D, Maitinez D, Grinan T, Brito V, Macias A et al.:Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotypeantibody. J Immunol 181(9) :6625-6634, 2008.
 
P.61 掲載の参考文献
1) Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M:Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 47:143-152, 2008.
PubMed
2) Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S et al.:Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73:1959-1961, 2002.
PubMed
3) Ogura Y, Hori T, El Moghazy WM, Yoshizawa A, Oike F et al.:Portal pressure < 15mm Hg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. Liver Transpl 16:718-728, 2010.
 
4) Yoshizawa A, Sakamoto S, Ogawa K, Kasahara M, Uryuhara K et al:New protocol of immunosuppression for liver transplantation across ABO barrier:the use of rituximab, hepatic arterial infusion, and preservation of spleen. Transplant Proc 37:1718-1719, 2005.
PubMed
5) Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H et al.:Rituximab, IVIG, and plasma exchange without graft local infusion treatment:a new protocol in ABO incompatible living donor liver transplantation. Transplantation 88:303-307, 2009.
PubMed
P.67 掲載の参考文献
1) Farges O, Kalil AN, Samuel D, Saliba F, Arulnaden JL et al:The use of ABO-incompatible grafts in liver transplantation:a life-saving Procedure in highly selected patients. Transplantation 59(8) :1124-1133, 1995.
PubMed
2) Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S et al:Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73(12) :1959-1961, 2002,
PubMed
3) Alexandre GPJ, Squifflet JP, De Buruyere M, Latinne D, Moriau M et al.:Splenectomy as a prerequisite for successful human ABO-incompatible renal transplantation. Transplant Proc 17(1) :138-143, 1985.
 
4) 高橋公太:わが国におけるABO血液型不適合腎移植の統計:第7回アンケート調査報告. 今日の移植 16 (6) :543-554, 2003.
 
5) Toma H:ABO-incompatible renal transplantation. Urol Clin North Am 21(2) :299-310, 1994.
PubMed
6) Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H et al.:Rituximab, IVIG, and plasma exchange without graft local infusion treatment:a new protocol in ABO incompatible living donor liver transplantation. Transplantation 88(3) :303-307, 2009.
PubMed
7) Testa G, Vidanovic V, Chejfec G, Gangemi A, Iqpal R et al:Adult living-donor liver transplantation with ABO-incompatible grafts. Transplantation 85(5) :681-686, 2008.
PubMed

書評

最近チェックした商品履歴

Loading...